Expat's big plans to improve Anglo-Aussie ties
15 August, 2003 by Melissa TrudingerExpatriate Australian Dr John Sime is headed back to Australia next January, with plans to improve the links between the Australian and the British biotechnology industries.
GroPep cuts its losses to produce second-half profit
15 August, 2003 by Iain ScottAdelaide-based GroPep has continued to shuck off the disastrous after-effects of its purchase of Biotech Australia by posting a second-half profit for 2002-03.
BresaGen announces major restructure plans
14 August, 2003 by Iain ScottBresaGen (ASX:BGN) intends to spin off its protein pharmaceuticals business and headquarter it in the US, as part of a major restructure.
Shotgun weddings leading to useful new hybrids
14 August, 2003 by Graeme O'NeillYou're a plant geneticist, and you want to extend the range of the world's most important human food crop, rice (Oryza sativa) into cooler regions of the world.
Polartechnics eyes US capital market
14 August, 2003 by Jeremy TorrCapitalising on the successful release of its innovative Pap smear diagnostic into the European market, Polartechnics has dipped a toe into the US investment scene with the appointment of a New York investment banker as strategic advisor.
Herbal remedy fails cholesterol test - US study
13 August, 2003 by Staff WritersAn herbal remedy derived from the mukul myrrh tree and used in India to relieve heart symptoms actually raised cholesterol levels instead of lowering them as advertised, researchers said.
Acrux claims success in Phase I anxiety trial
13 August, 2003 by Melissa TrudingerMelbourne drug delivery company Acrux has successfully completed a Phase I clinical study for its proprietary buspirone metered-dose transdermal spray (MDTS) for the treatment of anxiety.
Eiffel to collaborate with UK asthma company
11 August, 2003 by Jeremy TorrMelbourne biotech Eiffel Technologies has signed an agreement with a UK-based drug delivery company, Meridica, to reengineer asthma therapeutics for use in a new technology inhalation device.
Evogenix teams with UK firm Domantis
11 August, 2003 by Melissa TrudingerEvoGenix has signed an agreement with UK-based Domantis to apply its protein evolution and optimisation technology to one of Domantis's domain antibody therapeutic leads.
West Nile lookalike gives vaccine hope
08 August, 2003 by Jeremy TorrResearchers at the University of Queensland have developed a clone of the locally endemic Kunjin virus, and successfully trialled in mice it as a West Nile virus (WNV) vaccine.
Polartechnics ramps up for Italian job
08 August, 2003 by Jeremy TorrDevice maker Polartechnics is to focus on the Italian market for the introduction of its TruScreen cervical cancer diagnostic device, as a precursor to a major push into the European screening arena.
CSIRO licenses bio-bone
08 August, 2003 by Jeremy TorrCSIRO has formed a strategic alliance with UK-based medical device company AorTech producing spinal disc implants, using a unique polymer developed by Melbourne researchers.
Prima, Prana to team on Alzheimer's vaccine
08 August, 2003 by Melissa TrudingerMelbourne biotechs Prima BioMed and Prana Biotechnology will collaborate on a project to develop a vaccine for Alzheimer's disease, the companies announced today.
Ambri seals deal with Sydney biomed network
07 August, 2003 by Jeremy TorrBiosensor company Ambri is to set up a clinical trial and research link with Sydney's Royal North Shore Hospital as part of a wider deal with the BioMed North group of medical facilities.
Premier Bionics claims sleep trial success
07 August, 2003 by Melissa TrudingerPremier Bionics has announced a successful clinical trial for its AirwayClear device for non-invasive detection and diagnosis of obstructive sleep apnoea (OSA), providing support for commercial discussions and laying the groundwork for a larger trial.
